Unicycive Therapeutics (UNCY) PT Raised to $22 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $22.00 (from $9.00) while maintaining a Buy rating.

The analyst commented: 'On October 28, Unicycive announced that based on the minutes received from the FDA after their Type A meeting the company plans to file a response to the Complete Response Letter (CRL) by year-end and expects a decision in 1H26. Recall, Unicycive filed a new drug application (NDA) to market their lead drug, oxylanthanum carbonate (OLC) as a therapy for hyperphoshatemia and received the CRL from the FDA in June due to a cGMP compliance-related deficiency that the agency found with Unicycive’s third-party manufacturing vendor, a subcontractor to Unicycive’s CDMO. Additionally, management stated that the company closed 3Q25 with $42M in cash providing financial runway into 2027. We maintain our Buy rating on UNCY and raise our 12-month price target to $22 per diluted share from prior $9.00."

You May Also Be Interested In

• Unicycive Therapeutics (UNCY) PT Lowered to $25 at Guggenheim
• Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
• Applied Aerospace & Defense (AADX) PT Lowered to $23 at BofA Securities